We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Based 5- and 10-Year Follow-Up After Two Clinical Trials

MedXY Editorial Team•Jun 10, 2026•Cardiology
cardiometabolic healthlifestyle interventionMRItype 2 diabetesvisceral fat

Title

Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Based 5- and 10-Year Follow-Up After Two Clinical Trials

Summary

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems ModelingThis study uses longitudinal modeling to compare tirzepatide and semaglutide’s effects on fasting glucose in type 2 diabetes, revealing tirzepatide’s superior control largely due to greater insulin-independent hepatic glucose production supSep 23, 2026Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World StudyEmpagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced abSep 23, 2026GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort StudyA comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.Sep 19, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World Data
Fenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.
Sep 18, 2026
Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled TrialsThe effectiveness of lifestyle interventions promoting physical activity for diabetes risk reduction varies by prediabetes phenotype, with individuals having impaired fasting glucose showing the least response. Tailored approaches may enhanSep 17, 2026
Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative AnalysisAmong type 2 diabetes patients using GLP-1 receptor agonists, oxycodone is linked to higher short-term risks of severe gastrointestinal complications compared to hydrocodone and tramadol, warranting cautious opioid selection in this populatSep 15, 2026